Table 3.
No. events/cases2 | HR3 | p value | |
---|---|---|---|
Gleason score ≤6 | |||
T | 32/447 | 0.90 (0.58–1.40) | 0.64 |
SHBG | 32/447 | 1.07 (0.70–1.63) | 0.77 |
SHBG-adjusted T4 | 32/447 | 0.77 (0.43–1.38) | 0.38 |
Free T | 20/336 | 1.06 (0.63–1.77) | 0.83 |
DHT5 | 26/326 | 0.99 (0.62–1.57) | 0.95 |
AAG | 32/446 | 1.13 (0.83–1.55) | 0.44 |
Estradiol | 32/447 | 1.08 (0.72–1.63) | 0.71 |
Gleason score 7 | |||
T | 42/295 | 0.93 (0.66–1.31) | 0.68 |
SHBG | 42/295 | 1.14 (0.77–1.69) | 0.50 |
SHBG-adjusted T4 | 42/295 | 0.82 (0.49–1.36) | 0.44 |
Free T | 22/223 | 0.96 (0.55–1.68) | 0.88 |
DHT5 | 37/211 | 0.86 (0.55–1.34) | 0.50 |
AAG | 42/294 | 1.08 (0.84–1.39) | 0.55 |
Estradiol | 42/295 | 1.06 (0.75–1.49) | 0.75 |
Gleason score 8–10 | |||
T | 37/98 | 1.06 (0.72–1.56) | 0.78 |
SHBG | 37/98 | 1.04 (0.77–1.40) | 0.81 |
SHBG-adjusted T4 | 37/98 | 1.05 (0.63–1.73) | 0.86 |
Free T | 23/68 | 1.36 (0.74–2.52) | 0.32 |
DHT5 | 30/75 | *1.87 (1.26–2.78) | *0.002 |
AAG | 37/98 | 1.21 (0.84–1.74) | 0.31 |
Estradiol | 37/98 | 1.31 (0.83–2.08) | 0.25 |
Stage T1/T2 | |||
T | 75/750 | 0.87 (0.66–1.15) | 0.33 |
SHBG | 75/750 | 1.02 (0.78–1.34) | 0.88 |
SHBG-adjusted T4 | 75/750 | 0.79 (0.55–1.14) | 0.21 |
Free T | 45/569 | 1.05 (0.73–1.51) | 0.79 |
DHT5 | 62/546 | 0.98 (0.72–1.32) | 0.87 |
AAG | 75/749 | 1.14 (0.93–1.39) | 0.21 |
Estradiol | 75/750 | 0.96 (0.73–1.27) | 0.79 |
Stage T3 | |||
T | 24/115 | 1.12 (0.57–2.20) | 0.75 |
SHBG | 24/115 | *1.59 (1.05–2.41) | *0.03 |
SHBG-adjusted T4 | 24/115 | 0.63 (0.26–1.52) | 0.31 |
Free T | 14/77 | 0.93 (0.39–2.23) | 0.87 |
DHT5 | 21/93 | *1.98 (1.30–3.00) | *0.001 |
AAG | 24/115 | 1.12 (0.80–1.56) | 0.52 |
Estradiol | 24/115 | 1.38 (0.74–2.57) | 0.32 |
| |||
Stage T4/N1/M1 | |||
T | 44/53 | 1.14 (0.65–2.02) | 0.65 |
SHBG | 44/53 | 0.77 (0.54–1.10) | 0.15 |
SHBG-adjusted T4 | 44/53 | 1.56 (0.82–2.98) | 0.18 |
Free T6 | – | – | – |
DHT5 | 40/47 | 1.11 (0.70–1.78) | 0.66 |
AAG | 44/52 | 0.73 (0.45–1.20) | 0.21 |
Estradiol | 44/53 | 0.93 (0.72–1.21) | 0.61 |
Age <65 yr | |||
T | 34/252 | 1.02 (0.73–1.42) | 0.92 |
SHBG | 34/252 | 1.21 (0.83–1.77) | 0.33 |
SHBG-adjusted T4 | 34/252 | 0.94 (0.60–1.47) | 0.79 |
Free T | 8/173 | 1.08 (0.51–2.26) | 0.84 |
DHT5 | 31/193 | 1.36 (0.96–1.94) | 0.09 |
AAG | 34/251 | 0.81 (0.59–1.12) | 0.21 |
Estradiol | 34/252 | 0.82 (0.53–1.26) | 0.36 |
Age ≥65 yr | |||
T | 111/684 | 0.97 (0.77–1.23) | 0.83 |
SHBG | 111/684 | 1.17 (0.96–1.44) | 0.13 |
SHBG-adjusted T4 | 111/684 | 0.79 (0.58–1.07) | 0.13 |
Free T | 67/489 | 1.01 (0.73–1.40) | 0.95 |
DHT5 | 92/512 | 1.16 (0.93–1.46) | 0.19 |
AAG | 111/683 | 1.12 (0.94–1.34) | 0.21 |
Estradiol | 111/684 | 1.17 (0.96–1.44) | 0.13 |
Interval <2 yr | |||
T | 39/219 | 0.91 (0.54–1.51) | 0.70 |
SHBG | 39/219 | 1.18 (0.81–1.74) | 0.39 |
SHBG-adjusted T4 | 39/219 | 0.75 (0.42–1.35) | 0.34 |
Free T | 28/197 | 1.05 (0.65–1.67) | 0.86 |
DHT5 | 38/213 | *1.69 (1.17–2.44) | *0.005 |
AAG | 39/219 | 0.92 (0.66–1.29) | 0.63 |
Estradiol | 39/219 | 1.05 (0.77–1.42) | 0.77 |
Interval ≥2 yr | |||
T | 106/717 | 0.95 (0.78–1.16) | 0.62 |
SHBG | 106/717 | 1.19 (0.96–1.46) | 0.11 |
SHBG-adjusted T4 | 106/717 | 0.80 (0.60–1.08) | 0.15 |
Free T | 50/472 | 0.88 (0.60–1.29) | 0.50 |
DHT5 | 85/492 | 1.08 (0.84–1.37) | 0.56 |
AAG | 106/715 | 1.04 (0.88–1.23) | 0.66 |
Estradiol | 106/717 | 1.08 (0.86–1.35) | 0.51 |
AAG = androstanediol glucuronide; BMI = body mass index; DHT = dihydrotestosterone; HPFS = Health Professionals Follow-up Study; HR = hazard ratio; PHS = Physicians’ Health Study; SHBG = sex hormone binding globulin; T = testosterone.
Free T not measured in PHS.
When possible, men with missing values were included in the analysis using a missing indicator variable. In some subsets the number of men with missing values was too small (≤5%) to ensure model convergence, so these men were excluded from the analysis.
HR: adjusted for age at diagnosis, BMI, physical activity, and smoking status. HR represents change per unit interquartile range in batch-adjusted continuous measure of each hormone.
HR as above but further adjusted for SHBG.
DHT data not available for third HPFS batch.
Analysis not performed due to insufficient sample size for subset.